Skip to content

About
Science
Pipeline
Leadership
News & Resources
Expanded Access
Contact

Press

Nature BioPharmDealmakers: SurVaxM, bench to bedside.

As published in Nature BioPharmDealmakers, June 2024.

← Back to News & Resources

Nature BioPharmDealmakers feature: Developing a new cancer immunotherapy, SurVaxM from bench to bedside

Elm & Carlton Streets
Buffalo, NY 14263

A clinical-stage immunotherapy company disrupting cancer, one patient at a time.

Company

About
Science
Pipeline
Leadership

Resources

News & Publications
Expanded Access Policy
Privacy Policy
For Partners

Contact

General inquiries
Patients & caregivers: please ask your treating physician to contact us directly, or read our Expanded Access Policy.

MimiVax is a privately held company. SurVaxM® is an investigational product and has not been approved by the U.S. Food and Drug Administration. Nothing on this site constitutes medical advice; eligibility for clinical trials or expanded access should be discussed with a treating physician. See our Expanded Access Policy and Privacy Policy.

© 2026 MimiVax, Inc.